Sunshine Biopharma (SBFM) Other Non-Current Assets (2017 - 2026)
Sunshine Biopharma (SBFM) posted Other Non-Current Assets of $71740.0 for Q1 2026, up 845.19% on a QoQ basis from $7590.0 in Q4 2020.
Sunshine Biopharma (SBFM) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Sunshine Biopharma's Other Non-Current Assets history runs 5 years deep, the most recent figure standing at $71740.0 for Q1 2026.
- Quarterly Other Non-Current Assets changed N/A year-over-year to $71740.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71740.0 (changed N/A YoY) and the FY2020 annual result came in at $7590.0, changed 0.0% from the prior year.
- Other Non-Current Assets was $71740.0 for Q1 2026 at Sunshine Biopharma, up from $7590.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $71740.0 in Q1 2026 and bottomed at $71740.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 233.20 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | 169,000.00 |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Sunshine Biopharma | 750,608.81 | -6.16 Mn | 2.18 Mn | 71,740.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 71,740.00 |
| Dec 31, 2020 | 7,590.00 |
| Dec 31, 2019 | 7,590.00 |
| Jun 30, 2019 | 989,572.00 |
| Mar 31, 2019 | 989,572.00 |
| Dec 31, 2018 | 989,572.00 |
| Mar 31, 2018 | 7,756.00 |
| Dec 31, 2017 | 80,290.00 |